01 9Toviaz
Main Therapeutic Indication : Nephrology
Currency : USD
2019 Revenue in Millions : 250
2018 Revenue in Millions : 271
Growth (%) : -8
Main Therapeutic Indication : Nephrology
Currency : USD
2020 Revenue in Millions : 252
2019 Revenue in Millions : 250
Growth (%) : 1
Main Therapeutic Indication : Nephrology
Currency : USD
2021 Revenue in Millions : 238
2020 Revenue in Millions : 252
Growth (%) : -6
Main Therapeutic Indication : Urology
Currency : USD
2022 Revenue in Millions : 146
2021 Revenue in Millions : 238
Growth (%) : -39
Main Therapeutic Indication : Urology
Currency : USD
2015 Revenue in Millions : 288
2014 Revenue in Millions : 267
Growth (%) : -7%
Main Therapeutic Indication : Urology
Currency : USD
2014 Revenue in Millions : 22.50%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Urology
Currency : USD
2016 Revenue in Millions : 258
2015 Revenue in Millions : 267
Growth (%) : -3
Main Therapeutic Indication : Urology
Currency : USD
2017 Revenue in Millions : 257
2016 Revenue in Millions : 258
Growth (%) : -0.4
Main Therapeutic Indication : Renal Disorders
Currency : USD
2018 Revenue in Millions : 270
2017 Revenue in Millions : 257
Growth (%) : 5%
LOOKING FOR A SUPPLIER?